News & CommentCANCER

The Roadblocks to Angiogenesis Blockers

See allHide authors and affiliations

Science  15 May 1998:
Vol. 280, Issue 5366, pp. 997
DOI: 10.1126/science.280.5366.997

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Although compounds that block the development of new blood vessels have shown great promise in treating cancer in mice, human clinical trials are still at least 2 years away, according to researchers, in part because it is not yet possible to produce the necessary quantities of the compounds. So experts on cancer drugs were surprised by the heated speculation last week over two of these so-called antiangiogenesis compounds, angiostatin and endostatin.